CMXC green as breakout looms
Published: Thu, 05/04/17
 SMS alerts can make the difference between a profitable trade and a missed opportunity. Text “alert” to 97000 to receive our instant, reliable and free SMS alerts. Good morning all, Dip buyers in CMXC this morning are sitting pretty right now, well positioned to take advantage of a possible breakout. Unfortunately CMXC gapped up at the bell, but quickly retreated back to $0.40 where buyers were waiting. It then immediately bounced back to $0.45, right where multi-day resistance is - the key breakout level I outlined in my email below. Since then, the sellers at $0.45 have slowly been chipped away at. If we see some more buying today, we could see the start of a long awaited technical breakout. For those looking to trade CMXC, its definitely something to think about. Make sure CMXC remains on your trading screen today and tomorrow, and be in a position to take advantage. All the best. SmallCapMomo.com ------------------------------------------------------------------------------------------------------- Hello fellow investors / traders, I'm turning my focus to a potentially longer term trade idea.
Today's trade idea is CMXC. We first alerted you to CMXC a month or so ago when its was trading at $0.36, it jumped 10% on the day, and then ran to $0.46 over the next couple days for a solid 27% gain. CMXC closed yesterday at $0.41. As you can see in the chart below there is a double top formation at $0.45, where it was back in late March and tested again today. CMXC has been on a steady rise over the past couple of weeks. If this momentum continues, I think there is a good possibility we could see a breakout through this $0.45-0.46 resistance level and make new 52 week highs. In addition, popular investing website BarChart.com rates CMXC an 88% strong buy on its short, medium and longer term indicators. Cell MedX Corp. (OTCQB:CMXC) is an early development stage biotech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson’s disease, high blood pressure. Cell MedX’s proprietary technology is the eBalance”, which is in the research and development stage to manage diabetes mellitus and its complications. The company recently cut over $800k off its current liabilities between its last two reporting periods by converting those liabilities to stock ownership. CMXC also began to move forward with renewed focus after divesting its Avyonce Cosmedics segment in late January. In our experience, that tends to foster greater success in primary segments, particularly in biotech ventures. In this case, the primary segment is the company’s eBalance technology, a proprietary method for the application of bioelectric signaling to treat diabetes and related ailments. The eBalance device uses a microcurrent-stimulation process that does the work of a healthy metabolism to reduce numbness, tingling or pain in arms or legs of diabetic patients. Cell MedX believes it can also improve glucose control, insulin resistance and blood pressure issues. Early observations show that eBalance has already shown very positive results in insulin dependent diabetics. The primary catalyst for the company now is its Observational Study in the main research facility in Hamilton, Ontario. The company just announced that Dr. Richard Tytus, the Lead Investigator, and his team have commenced screening for qualified subjects. The Observational Clinical Trial has been designed to assess the impact of three months of eBalance therapy as an adjunct treatment, on HbA1c in Type 1 and Type 2 diabetics. The secondary endpoints of the Trial will observe changes from baseline and medical history in the following;
The Company received Health Canada’s approval to commence the Study on January 12, 2017. The detailed information of the Study will be posted on clinicaltrials.gov upon approval of government regulatory agencies. As with all biotech's, the most exciting and explosive period is during key trials. The market is coming to terms with this technology and its market implications. To learn more about CMXC, visit their website at http://www.cellmedx.com In Summary... We think CMXC looks look a hot trade idea, both on a technical level, and based on the news catalysts the company has been announcing to the market. There could be some nice gains made if CMXC can break through to new 52 week highs in the coming days. BarChart.com agrees, rating CMXC an 88% strong buy. Get CMXC on your screen now and be ready for a potentially big trading day ahead. --------------------------------------------------------------------------------------------------------
Remember our key trading rules when trading. Capital preservation is key. Keep your stops tight, and if things don't go your way, cut your losses and look for another opportunity. Disclaimer Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. For full disclaimer click here. SmallCapMomo.com employees are not registered as an Investment Adviser in any jurisdiction whatsoever. The disclaimer is to be read and fully understood before using our site, or joining our email list. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SmallCapMomo.com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. SmallCapMomo.com does not offer such advice or analysis, and SmallCapMomo.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements". Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, SmallCapMomo.com has relied upon information supplied by its customers, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SmallCapMomo.com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents have not completed any due diligence or research on the companies advertised herein and disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SmallCapMomo.com is not responsible for any claims made by the companies advertised herein. SmallCapMomo.com may receive compensation and they, its employees and/or affiliates may own stock that they have purchased in the open market either prior, during, or after the release of the companies profile which is an inherent conflict of interest in SmallCapMomo.com statements and opinions and such statements and opinions cannot be considered independent. SmallCapMomo.com reserves the right to buy and sell shares of the profiled company on the open market before, during or after the release of the company profile. In such an event, SmallCapMomo.com will not update its disclaimer to reflect any shares bought or sold on the open market during the profile coverage. SmallCapMomo.com and its management may benefit from any increase in the share price of the profiled companies and hold the right to close positions they have entered into at any given time including before or after the release of the companies profile. SmallCapMomo.com has been compensated three thousand dollars via electronic transfer from a non-affiliated third party Cream Consulting for the profile of CMXC. SmallCapMomo.com does not accept compensation in restricted or free-trading shares for its marketing services of the company being profiled. However the third party that has compensated SmallCapMomo.com may hold free-trading shares of the company being profiled and could very well be selling shares of the company’s stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration. If SmallCapMomo.com ever does accept compensation in the form of restricted or free trading shares of the company being profiled and decides to sell these shares into the public market at any time before, during, or after the release of the companies profile our disclaimer will be updated accordingly reflecting the position of those free trading shares received as compensation for our services at the time our promotional material is released to the public, as well as information on our intention to sell these shares during the promotional period or thereafter. Text ALERT to 97000. You will receive auto-dialed text alerts from SmallCapMomo.com. No consent req'd for purchase. Msg & data rates may apply. Msg frequency varies. Reply STOP to stop, HELP for help. Terms: http://97000.co/t. Privacy policy: http://97000.co/h. |